Medication info
Hanwha Rocan Tablet 20/32 mg (Rosuvastatin Calcium, Candesartan Cilexetil)

Hanwha Rocan Tablet 20/32 mg (Rosuvastatin Calcium, Candesartan Cilexetil)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletCandesartan Cilexetil›32mg / 1 tablet
Manufacturer / importer
Hanwha Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/PTP X 3)
Approval status
Active

MFDS item code 202301656 · Approved 2023.05.24 · Insurance code 651602890

Summary

Main use
Treatment of lipid disorders, hypertension, and heart failure; inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose in patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose in patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout treatment. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose of this drug is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
○ Candesartan cilexetil 1. Essential hypertension 6) Children: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. 2. Heart failure 3) Children: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Hanwha Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of lipid disorders, hypertension, and heart failure; inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • impaired left ventricular systolic function
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol
  • smoking
View approved original text

This drug is used when two medications are needed simultaneously. Candesartan Cilexetil is used for the treatment of essential hypertension and in heart failure patients with impaired left ventricular systolic function who require additional therapy to ACE inhibitors or are intolerant to them. Rosuvastatin is used as an adjunct to dietary therapy in patients with hypercholesterolemia and mixed dyslipidemia, particularly reducing LDL cholesterol levels in patients with hypercholesterolemia, thus delaying the progression of atherosclerosis. It also helps reduce the risks of stroke, myocardial infarction, and arterial revascularization procedures in patients at high risk of cardiovascular disease. Therefore, this medication is used to manage hypertension, heart failure, and hyperlipidemia simultaneously to improve cardiovascular health.

How to take

Adult dose

This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil/rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose in patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose in patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: The recommended initial dose is 4 mg once daily. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout treatment. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score above 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligram dose of this drug is contraindicated in some of these patients. For patients taking candesartan cilexetil and rosuvastatin concomitantly, they may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

○ Candesartan cilexetil 1. Essential hypertension 6) Children: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. 2. Heart failure 3) Children: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This drug can cause serious harm to the fetus when taken during pregnancy, especially in the second and third trimesters, so it should be stopped immediately if pregnancy is confirmed. It should not be used in patients with hypersensitivity to the drug, severely impaired liver function, pregnant or nursing women, and patients with muscle disorders. Use of this drug is prohibited or requires caution in patients with severe kidney disease or those taking certain other medications. Close monitoring is necessary for the elderly, patients with weakened liver function, and patients with hyperkalemia when taking this medication, and regular liver function tests and muscle-related tests should be performed. This drug may cause muscle-related side effects such as muscle pain or weakness; if these symptoms occur, consult a healthcare professional immediately. Moreover, since this drug can affect liver function, it should be discontinued if liver enzyme test results exceed three times the normal upper limit. Interactions may occur when taken with other antihypertensive or cholesterol-lowering medications, so it is essential to inform healthcare providers about other medications being taken. This drug is not recommended for children, as its safety and efficacy in this population have not been established. Caution is advised as dizziness may occur while driving or operating machinery, and it should be stored out of reach of children.

Side effects

Headache, nasopharyngitis, localized infection, periodontitis, chest discomfort, fatigue, inflammation, generalized pruritus, dermatitis, itching, joint stiffness, musculoskeletal pain, neck pain, limb pain, cataract, photophobia, dyspepsia, nausea, hyperglycemia, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, tooth extraction, orthostatic dizziness, miliaria, foreign body sensation, hyperglycemia, decreased serum sodium, hypoglycemia, nephrolithiasis, cough, tooth extraction, itching, nausea, dizziness, myalgia, myopathy, rhabdomyolysis, muscle weakness, constipation, abdominal pain, pancreatitis, rash, urticaria, myopathy, rhabdomyolysis, interstitial lung disease, hepatic failure, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, insomnia, nightmares, amnesia, peripheral neuropathy, thrombocytopenia, rash, urticaria, angioedema, myalgia, low back pain, dizziness, low back pain, muscle weakness, fever, paresthesia, tachycardia, palpitations, hyperglycemia, hypertriglyceridemia, hyperuricemia, anxiety, drowsiness, dyspnea, rash, increased sweating, hematuria, shock, syncope, loss of consciousness, paralysis, hypertonicity, syncope, facial flushing, weight gain, facial edema, polydipsia, sleep disorders, decreased libido, forgetfulness, anorexia, increased appetite, tinnitus, dysgeusia, erectile dysfunction, hypotension, hyperkalemia, kidney function impairment, increased creatinine, increased urea, increased potassium, increased ALT, increased AST, increased γ-GTP, liver dysfunction, jaundice, angioedema, rhabdomyolysis, arthralgia, myalgia, low back pain, kidney function impairment, acute renal failure, interstitial pneumonia, shock, syncope, loss of consciousness, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine, increased CK, joint pain, numbness, sensory disturbance, chest discomfort, anorexia, abdominal distention, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to protect it from air and moisture. The appropriate storage temperature is room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness and prevent degradation.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.